Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in Canada
Canadian Journal of Infectious Diseases & Medical Microbiology, 06/21/2012
Monfared AAT et al. – In Canada, posaconazole appears to be cost–saving relative to standard azole therapy in invasive fungal infection (IFI) prevention among high–risk neutropenic patients.



